Exclusive Summary

• The product has obtained US FDA GMP certification and is registered in the US, indicating high international quality standards and readiness to meet global demand for quality generics.
• Levetiracetam Extended-release Tablets, as a first-line antiepileptic drug and listed in the WHO Essential Medicines List, has significant clinical demand and broad market acceptance globally.
• The generic product offers a clear cost advantage over the originator drug, providing partners with better profit margins and market competitiveness.
• Despite being in a competitive market due to the expiration of originator patents, its efficacy and extended-release formulation offer a strong position in regions with high unmet needs for epilepsy treatment.
• The Chinese supplier, seeking distribution partnerships, can leverage the product's existing registrations and certifications to quickly enter target markets and reduce time-to-market.